Certican 0.25mg Tablet

Certican 0.25mg Tablet contains Everolimus as its active ingredient. It belongs to the class of drugs known as mTOR inhibitors and is used to prevent organ rejection in transplant patients and to treat certain types of cancer. Everolimus works by inhibiting the activity of a protein called mTOR (mammalian target of rapamycin), which is involved in cell growth, proliferation, and survival.

Active Ingredient:

• Everolimus: Everolimus is an mTOR inhibitor that blocks the activity of mTOR, a protein responsible for regulating cell growth and proliferation. By inhibiting mTOR signaling, Everolimus suppresses the immune response and slows down the growth of cancer cells.

Uses:

Certican 0.25mg Tablet is indicated for the following conditions:

1. Prevention of organ rejection in patients who have undergone kidney, liver, heart, or other organ transplantation.
2. Treatment of certain types of cancer, including advanced kidney cancer, advanced breast cancer, and certain types of neuroendocrine tumors.

Mechanism of Action:

Everolimus inhibits the activity of mTOR, a key regulator of cell growth and proliferation. By blocking mTOR signaling, Everolimus slows down cell cycle progression, reduces the production of proteins involved in cell growth and survival, and induces cell death in cancer cells. In transplant patients, Everolimus suppresses the immune response, preventing the rejection of transplanted organs.

Administration:

Certican 0.25mg Tablet is taken orally, usually once daily, with or without food. The dosage and duration of treatment may vary depending on the patient’s medical condition, response to treatment, and presence of side effects. It is important to take the medication consistently at the same time each day to maintain stable blood levels.

Side Effects:

Common side effects of Certican 0.25mg Tablet may include:

• Increased susceptibility to infections
• Fatigue
• Diarrhea
• Nausea
• Mouth sores
• Rash
• Elevated blood sugar levels
• Changes in blood cell counts

Precautions:

• Regular monitoring of kidney function, blood cell counts, and blood levels of Everolimus is essential during treatment.
• Avoid exposure to sunlight and ultraviolet (UV) light, as Everolimus may increase the risk of skin cancer and other skin conditions.
• Inform healthcare providers about all current medications, including over-the-counter drugs and supplements, as they may interact with Everolimus.
• Everolimus may impair wound healing, so caution should be exercised in patients undergoing surgery or with open wounds.

Contraindications:

Certican 0.25mg Tablet is contraindicated in patients with:

• Hypersensitivity to Everolimus or any component of the formulation.
• Severe liver impairment.
• Pregnancy or breastfeeding.